Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-05-01, Stock:NVS, The news for the past five days is as follows:
2019-04-24: NEWS1: Most-Bought European Stocks of Top Investors.NEWS2: Pharma Giant Eyes Better 2019 Profit And 3 New Blockbuster Hopefuls.NEWS3: Biogen says it will not give up on Alzheimer’s after failed trials.NEWS4: Novartis (NVS) Q1 Earnings Beat Estimates, Revenues Up Y/Y.NEWS5: Novartis (NVS) Q1 Earnings Beat Estimates, Revenues Up Y/Y.NEWS6: (OFFICIAL)-Novartis mulling $1.5 mln-$5 mln price range for SMA gene therapy.NEWS7: Novartis Stock Is Up Because Its Profit Beat Forecasts, and the CEO Is Upbeat.NEWS8: Novartis (NVS) Q1 Earnings Beat Estimates, Revenues Up Y/Y.NEWS9: Novartis Earnings Beat But Drug Giant&apos;s Sales Miss.NEWS10: The Daily Biotech Pulse: FDA Greenlights AbbVie's Psoriasis Drug, Novartis Earnings, Patent Notification For MediciNova.NEWS11: Novartis shares rise as Swiss drugmaker lifts 2019 profit outlook.NEWS12: Novartis: 1Q Earnings Snapshot.NEWS13: Novartis upgrades 2019 profit guidance on strong sales growth.NEWS14: Novartis boosts 2019 outlook on rising Cosentyx, Entresto sales.NEWS15: StockBeat - Elliott Effect Lifts SAP, as Softbank Bets on Wirecard.
2019-04-25: nan
2019-04-26: NEWS1: Is This Highly-Anticipated Gene Therapy in Trouble?.NEWS2: Is This Highly-Anticipated Gene Therapy in Trouble?.NEWS3: Is This Highly-Anticipated Gene Therapy in Trouble?.NEWS4: Is a Beat in Store for Glaxo (GSK) This Earnings Season?.NEWS5: Is a Beat in Store for Glaxo (GSK) This Earnings Season?.NEWS6: FDA approves biosimilar to Amgen&apos;s Enbrel.NEWS7: Novartis Raises Its 2019 Core Operating Income Guidance.NEWS8: Is a Beat in Store for Glaxo (GSK) This Earnings Season?.NEWS9: Novartis Reiterates Its 2019 Revenue Guidance.NEWS10: What Analysts Are Recommending for Novartis after Its Q1 Results.
2019-04-29: NEWS1: Is a Beat in the Cards for Incyte (INCY) in Q1 Earnings?.NEWS2: Why Novartis Earnings Provided A Bullish Signal For This Biotech Stock.NEWS3: Cannabis stocks mixed with Aleafia falling after earnings, Canopy updates on NYC hemp plans.NEWS4: Entresto: A Key Growth Driver for Novartis in Q1.NEWS5: A Look at Cosentyx, Novartis’s Fast-Growing Immunology Drug.NEWS6: Examining Novartis’s Performance by Segment in 2019.
2019-04-30: NEWS1: 5 Biotech Stocks for a Long-Lived Portfolio.NEWS2: Incyte (INCY) Q1 Earnings & Revenues Beat Estimates, Up Y/Y.NEWS3: Incyte (INCY) Q1 Earnings & Revenues Beat Estimates, Up Y/Y.NEWS4: Incyte (INCY) Q1 Earnings & Revenues Beat Estimates, Up Y/Y.NEWS5: Health Care Sector Update for 04/30/2019: LLY, PFE, NVS, JNJ, ABTX, MRK, AMGN.NEWS6: Health Care Sector Update for 04/30/2019: LLY, PFE, NVS, JNJ, ABTX, MRK, AMGN.NEWS7: Can 'synthetic lethality' and deep experience propel this cancer-fighting biotech's $70M IPO?.NEWS8: Novartis’s Oncology Business Continues Its Strong Showing in Q1.NEWS9: Is a Beat in the Cards for Incyte (INCY) in Q1 Earnings?.NEWS10: Is a Beat in the Cards for Incyte (INCY) in Q1 Earnings?.

Answer: Decrease